Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer

Gemcitabine (Gem) has been a standard first-line drug for pancreatic cancer (PCa) treatment; however, Gem's rapid metabolism and systemic instability (short half-life) limit its clinical outcome. The objective of this study was to modify Gem into a more stable form called 4-(N)-stearoyl-gemcita...

Descripción completa

Detalles Bibliográficos
Autores principales: Inkoom, Andriana, Ndemazie, Nkafu Bechem, Smith, Taylor, Frimpong, Esther, Bulusu, Raviteja, Poku, Rosemary, Zhu, Xue, Han, Bo, Trevino, Jose, Agyare, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182601/
https://www.ncbi.nlm.nih.gov/pubmed/37179357
http://dx.doi.org/10.1186/s12885-023-10928-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182601/
https://www.ncbi.nlm.nih.gov/pubmed/37179357
http://dx.doi.org/10.1186/s12885-023-10928-w

Ejemplares similares